What are the recommended indications, dosing regimens, contraindications, and monitoring requirements for topical and oral retinoids in the treatment of acne and photodamage?

Retinoids for Acne and Photodamage

Topical Retinoids

Topical retinoids are the cornerstone of acne therapy and should be used as first-line treatment for comedonal acne and as part of combination therapy for all inflammatory acne variants. 1 They work through comedolysis, prevention of microcomedone formation, and anti-inflammatory effects.

Available Agents and Formulations

Three FDA-approved topical retinoids exist for acne:

• Tretinoin: 0.025-0.1% (cream, gel, microsphere gel)
• Adapalene: 0.1%, 0.3% (cream, gel, lotion) - 0.1% available over-the-counter
• Tazarotene: 0.05%, 0.1% (cream, gel, foam)
• Trifarotene: newer agent with FDA approval 2

Each binds different retinoic acid receptors (tretinoin to alpha/beta/gamma; adapalene and tazarotene selectively to beta/gamma), conferring slight differences in activity and tolerability 1.

Dosing and Application

• Apply once daily, typically in the evening
• Start with lower concentrations or alternate-day application to minimize irritation
• Tretinoin should not be co-applied with benzoyl peroxide due to oxidation/inactivation
• Adapalene and tazarotene lack this restriction
• Use concurrent daily sunscreen due to photosensitivity risk 2

Indications

Primary indications:

• Comedonal acne (ideal as monotherapy)
• All inflammatory acne variants (in combination with other agents)
• Maintenance therapy after oral antibiotic discontinuation 1
• Post-inflammatory hyperpigmentation (particularly in Fitzpatrick skin types IV-VI)

For photodamage: Topical tretinoin ≥0.02% improves mild-to-severe photodamage; tazarotene 0.01-0.1% and isotretinoin 0.1% benefit moderate photodamage with 4-11 months treatment 3. Effects include collagen thickening and restoration 4.

Contraindications and Precautions

• Pregnancy: Tazarotene is Category X; tretinoin and adapalene require caution 5
• Common adverse effects: erythema, dryness, peeling, stinging (typically early treatment phase)
• Mitigate irritation through: lower concentrations, concurrent emollients, alternate-day dosing, short-contact therapy (30-60 minutes) 5, 2

Monitoring

No routine laboratory monitoring required for topical retinoids.

---

Oral Isotretinoin

Oral isotretinoin is FDA-approved for severe recalcitrant acne and should be initiated for moderate acne that is treatment-resistant, produces physical scarring, or causes significant psychosocial distress. 1

Indications

Strong indications:

• Severe nodular/nodulocystic acne
• Acne conglobata
• Acne fulminans (with concurrent prednisone 0.5-1 mg/kg/day)
• Moderate acne with: treatment resistance, rapid relapse after antibiotics, active scarring, or marked psychosocial impact 1
• Gram-negative folliculitis 6

Dosing Regimens

For severe acne:

• Start 0.5 mg/kg/day for first month
• Increase to 1.0 mg/kg/day thereafter as tolerated
• Target cumulative dose: 120-150 mg/kg (dose-dependent benefit plateaus beyond 150 mg/kg)
• Extremely severe cases may require lower starting doses ± oral corticosteroids 1

For moderate treatment-resistant acne:

• Low-dose isotretinoin: 0.25-0.4 mg/kg/day
• Efficacy comparable to conventional dosing
• Lower adverse effect rates, improved tolerability
• Relapse rates equal to conventional dosing (unlike severe acne) 1

Avoid intermittent dosing - associated with higher relapse rates and not recommended 1

Administration

• Take with food for optimal absorption (highly lipophilic)
• Exception: isotretinoin with lidose can be taken on empty stomach 1
• Treatment duration: typically 4 months (85% of patients); 15% require up to 10 months 7

Contraindications

Absolute:

• Pregnancy (highly teratogenic)
• Hypersensitivity to isotretinoin or parabens

Relative:

• Active inflammatory bowel disease (though causal relationship unproven) 1
• Severe hepatic dysfunction
• Severe hypertriglyceridemia

Monitoring Requirements

Mandatory:

• iPLEDGE program enrollment for all patients 1
• Females of childbearing potential: Two forms of contraception (including user-independent methods), monthly pregnancy tests, contraception counseling 1

Laboratory monitoring:

• Baseline: liver function tests, lipid panel (cholesterol, triglycerides)
• Repeat until response established, then as clinically indicated
• More frequent monitoring for patients with metabolic risk factors 1, 6
• Complete blood count NOT routinely required 1

Clinical monitoring:

• Screen for inflammatory bowel disease symptoms (abdominal pain, rectal bleeding, diarrhea)
• Monitor for depressive symptoms (though causal relationship remains unproven) 1
• Assess for mucocutaneous, musculoskeletal, and ophthalmic adverse effects 1

Common Adverse Effects

Most prevalent (dose-dependent, reversible):

• Mucocutaneous: cheilitis, xerosis, epistaxis
• Musculoskeletal: arthralgias, myalgias
• Ophthalmic: dry eyes, decreased night vision
• Hypertriglyceridemia, elevated transaminases 1

Critical Pitfalls

1. Underdosing severe acne: Using 0.5 mg/kg/day without escalation or achieving cumulative dose <120 mg/kg significantly increases relapse rates 1
2. Intermittent dosing: Never use - consistently shows higher relapse rates 1
3. Inadequate contraception counseling: Must emphasize user-independent methods and teratogenic risk 1
4. Premature discontinuation: Slow responders (macrocomedones, hormonal factors) require persistence, not abandonment 7